Arvinas, Inc. (ARVN)

31,44 -0,51 (-1,60%) Alla chiusura: 04:00PM EDT

Arvinas, Inc.

5 Science Park
395 Winchester Avenue
New Haven, CT 06511
United States
203 535 1456
https://www.arvinas.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 445

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. John G. Houston Ph.D.	Chairperson, CEO & President	1,14M	N/D	1960
Dr. Ian Taylor Ph.D.	Chief Scientific Officer	732,26k	N/D	1963
Mr. David K. Loomis M.B.A.	VP & Chief Accounting Officer	N/D	N/D	1974
Mr. Jeff Boyle	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Jared M. Freedberg J.D.	General Counsel & Corporate Secretary	N/D	N/D	1969
Mr. Steve Weiss	Senior VP & Chief Human Resources Officer	N/D	N/D	1970
Dr. John A. Grosso Ph.D.	Senior Vice President of R&D Technical Operations	N/D	N/D	1957
Dr. Randy Teel Ph.D.	Chief Business Officer	N/D	N/D	1980
Ms. Angela M. Cacace Ph.D.	Senior Vice President of Neuroscience & Platform Biology	N/D	N/D	1968
Mr. John P. Northcott	Chief Commercial Officer	N/D	N/D	1978

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Governance aziendale

L'ISS Governance QualityScore di Arvinas, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 8; diritti degli azionisti: 9; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.